MVI 118

Drug Profile

MVI 118

Alternative Names: AR vaccine - Madison Vaccines; pTVG-AR

Latest Information Update: 21 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Madison Vaccines
  • Developer Madison Vaccines; National Cancer Institute (USA); University of Wisconsin-Madison
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Androgen receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 01 Jul 2015 Phase-I clinical trials in Prostate cancer (Metastatic disease) in USA (Parenteral)
  • 23 Jan 2014 MVI 118 is available for licensing as of 23 Jan 2014.
  • 13 Jan 2014 Madison Vaccines plans a phase I trial for Prostate cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top